This question is timely in view of the recognised role of hyperglucagonaemic in human diabetes [3], the potential therapeutic benefit of glucagon antagonists for glycaemic control in diabetes [39], and current methods for assessment of glucokinase activity based on the assumption of exclusive control by glucose as opposed to hormones [15,16]. Here, GCK is linked to diabetes mellitus.